CA3196221A1 - Conjugated tlr7 and nod2 agonists - Google Patents
Conjugated tlr7 and nod2 agonistsInfo
- Publication number
- CA3196221A1 CA3196221A1 CA3196221A CA3196221A CA3196221A1 CA 3196221 A1 CA3196221 A1 CA 3196221A1 CA 3196221 A CA3196221 A CA 3196221A CA 3196221 A CA3196221 A CA 3196221A CA 3196221 A1 CA3196221 A1 CA 3196221A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- mmol
- alkoxy
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU102145 | 2020-10-21 | ||
| LULU102145 | 2020-10-21 | ||
| PCT/EP2021/079141 WO2022084417A1 (en) | 2020-10-21 | 2021-10-20 | Conjugated tlr7 and nod2 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3196221A1 true CA3196221A1 (en) | 2022-04-28 |
Family
ID=74175904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3196221A Pending CA3196221A1 (en) | 2020-10-21 | 2021-10-20 | Conjugated tlr7 and nod2 agonists |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230382886A1 (https=) |
| EP (1) | EP4232094A1 (https=) |
| JP (1) | JP2023546205A (https=) |
| CN (1) | CN116600830A (https=) |
| AU (1) | AU2021363606A1 (https=) |
| CA (1) | CA3196221A1 (https=) |
| WO (1) | WO2022084417A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024102639A1 (en) * | 2022-11-08 | 2024-05-16 | The Scripps Research Institute | N-arylpyrazole nod2 agonists as promoters of immune checkpoint inhibitor therapy |
| WO2025040743A1 (en) * | 2023-08-22 | 2025-02-27 | Univerza V Ljubljani | Conjugated tlr7 and rig-i agonists |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006242920A1 (en) | 2005-05-04 | 2006-11-09 | Pfizer Limited | 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C |
| CN101304748A (zh) | 2005-08-22 | 2008-11-12 | 加利福尼亚大学董事会 | Tlr激动剂 |
| US8138172B2 (en) | 2006-07-05 | 2012-03-20 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of TLR7 |
| CN101790380B (zh) * | 2007-02-07 | 2013-07-10 | 加利福尼亚大学董事会 | 合成tlr激动剂的缀合物及其应用 |
| BRPI0917013A2 (pt) | 2008-08-11 | 2016-02-16 | Glaxosmithkline Llc | métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto |
| KR20110117705A (ko) | 2009-02-11 | 2011-10-27 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 톨-유사 수용체 조정제 및 질병의 치료 |
| AU2011247358B2 (en) | 2010-04-30 | 2014-10-30 | Urogen Pharma Ltd. | Phospholipid drug analogs |
| WO2012038058A1 (en) | 2010-09-21 | 2012-03-29 | Telormedix Sa | Treatment of conditions by toll-like receptor modulators |
| US10471139B2 (en) * | 2013-08-15 | 2019-11-12 | The University Of Kansas | Toll-like receptor agonists |
| AU2017318601B2 (en) * | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
| US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
| WO2019197598A1 (en) | 2018-04-13 | 2019-10-17 | Glaxosmithkline Biologicals Sa | Tlr7 and / or tlr8 agonists |
| WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
-
2021
- 2021-10-20 JP JP2023524121A patent/JP2023546205A/ja active Pending
- 2021-10-20 CA CA3196221A patent/CA3196221A1/en active Pending
- 2021-10-20 US US18/032,612 patent/US20230382886A1/en active Pending
- 2021-10-20 EP EP21791419.1A patent/EP4232094A1/en active Pending
- 2021-10-20 CN CN202180085916.XA patent/CN116600830A/zh active Pending
- 2021-10-20 AU AU2021363606A patent/AU2021363606A1/en active Pending
- 2021-10-20 WO PCT/EP2021/079141 patent/WO2022084417A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021363606A9 (en) | 2025-01-09 |
| AU2021363606A1 (en) | 2023-06-01 |
| US20230382886A1 (en) | 2023-11-30 |
| CN116600830A (zh) | 2023-08-15 |
| WO2022084417A1 (en) | 2022-04-28 |
| JP2023546205A (ja) | 2023-11-01 |
| EP4232094A1 (en) | 2023-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260053911A1 (en) | Pyrimidine compound | |
| CN108794422B (zh) | 作为pd-l1抑制剂的杂环类化合物 | |
| US10640520B2 (en) | Boronic acid derivatives | |
| CN114989205A (zh) | 用于抑制精氨酸酶活性的组合物和方法 | |
| CN113150016A (zh) | 用于抑制精氨酸酶活性的组合物和方法 | |
| CN105813640A (zh) | 作为免疫调节剂的环肽类化合物 | |
| KR20170137725A (ko) | 데스아세톡시투불리신 h 및 이의 유사체 | |
| JP2020531591A (ja) | 相乗的抗癌活性を有する中間体薬剤およびポリエチレングリコール共役相乗的抗癌薬、ならびにその製造方法およびその使用 | |
| CN113614095B (zh) | 作为精氨酸酶抑制剂的烷基硼酸类化合物 | |
| CA3196221A1 (en) | Conjugated tlr7 and nod2 agonists | |
| US10576147B2 (en) | Muramyl peptide derivative compound, synthesis and uses thereof | |
| AU2017290238B2 (en) | Diprovocims: a new and potent class of TLR agonists | |
| CN112585142A (zh) | 新的抗疟疾化合物、制备方法及其用于耐药疟疾的用途 | |
| CN111491937A (zh) | 作为精氨酸酶抑制剂的杂环化合物 | |
| WO2023022231A1 (ja) | ウイルス感染症を処置または予防するための可逆的共有結合阻害物質 | |
| US10927147B2 (en) | Muramyl peptide derivative compound, synthesis and uses thereof | |
| WO2025093657A1 (en) | Conjugated tlr7 and tlr4 agonists | |
| WO2025040743A1 (en) | Conjugated tlr7 and rig-i agonists | |
| WO2020022892A1 (en) | Tubulysin derivatives and methods for preparing the same | |
| Wu | Modulators of Toll-like Receptors-4 and-2 | |
| HK1126114A (en) | Tlr agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241230 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241230 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241230 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250527 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250527 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250811 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250811 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250811 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250825 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250825 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251027 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260409 |